Using Menopausal Hormone Therapy After a Cancer Diagnosis in Ireland

Overview

Journal Ir J Med Sci

Specialty General Medicine

Date 2022 Feb 10

PMID 35141870

Authors

Fionan Donohoe

Yvonne OMeara

Aidin Roberts

Louise Comerford

Catherine M Kelly

Janice M Walshe

Deirdre Lundy

Martha Hickey

Donal J Brennan

Affiliations

Soon will be listed here.

Abstract

Background: Menopause may cause a constellation of symptoms that affect quality of life. Many women will have menopause induced or exacerbated by treatment for cancer whether that be through surgery, chemotherapy, radiotherapy, or anti-endocrine therapy. As treatments advance, the number of people living with and beyond a cancer diagnosis is set to increase over the coming years meaning more people will be dealing with the after effects of cancer and its treatment.

Aims: This review aims to summarise available data to guide clinicians treating women with menopausal symptoms after the common cancer diagnoses encountered in Ireland. The use of menopausal hormone therapy is discussed as well as non-hormonal and non-pharmacological options.

Conclusions: Managing menopausal symptoms is an important consideration for all physicians involved in the care of people living with and beyond a cancer diagnosis. High-quality data may not be available to guide treatment decisions, and, thus, it is essential to take into account the impact of the symptoms on quality of life as well as the likelihood of recurrence in each individual case.

Citing Articles

Menopausal Hormone Therapy in Breast Cancer Survivors.

Culhane R, Zaborowski A, Hill A Cancers (Basel). 2024; 16(19).

PMID: 39409888 PMC: 11475154. DOI: 10.3390/cancers16193267.

Psychometric validation of the Functional Assessment of Cancer Therapy-Endometrial among endometrial cancer patients.

Kim S, Noh J, Kim Y, Cho J, Kang D, Lee Y Cancer Med. 2024; 13(5):e7096.

PMID: 38466031 PMC: 10926879. DOI: 10.1002/cam4.7096.

References

Holmberg L, Iversen O, Rudenstam C, Hammar M, Kumpulainen E, Jaskiewicz J . Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008; 100(7):475-82. DOI: 10.1093/jnci/djn058. View

Tan D, Kaye S . Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol. 2006; 60(4):355-60. PMC: 2001101. DOI: 10.1136/jcp.2006.040030. View

Franco O, Chowdhury R, Troup J, Voortman T, Kunutsor S, Kavousi M . Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis. JAMA. 2016; 315(23):2554-63. DOI: 10.1001/jama.2016.8012. View

Finch A, Metcalfe K, Chiang J, Elit L, McLaughlin J, Springate C . The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol. 2011; 121(1):163-8. DOI: 10.1016/j.ygyno.2010.12.326. View

Stuenkel C, Davis S, Gompel A, Lumsden M, Murad M, Pinkerton J . Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(11):3975-4011. DOI: 10.1210/jc.2015-2236. View

Gershenson D . Management of borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol. 2016; 41:49-59. DOI: 10.1016/j.bpobgyn.2016.09.012. View

Calle E, Thun M, Heath Jr C . Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995; 87(7):517-23. DOI: 10.1093/jnci/87.7.517. View

Fahlen M, Fornander T, Johansson H, Johansson U, Rutqvist L, Wilking N . Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 2012; 49(1):52-9. DOI: 10.1016/j.ejca.2012.07.003. View

Col N, Hirota L, Orr R, Erban J, Wong J, Lau J . Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol. 2001; 19(8):2357-63. DOI: 10.1200/JCO.2001.19.8.2357. View

10.

Green S, Donegan E, Frey B, Fedorkow D, Key B, Streiner D . Cognitive behavior therapy for menopausal symptoms (CBT-Meno): a randomized controlled trial. Menopause. 2019; 26(9):972-980. DOI: 10.1097/GME.0000000000001363. View

11.

Gallup D, STOCK R . Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984; 64(3):417-20. View

12.

Vassilopoulou-Sellin R, Theriault R, Klein M . Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol. 1997; 65(1):89-93. DOI: 10.1006/gyno.1997.4621. View

13.

Morice P, Juncker L, Rey A, Haie-Meder C, Castaigne D . Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. Fertil Steril. 2000; 74(4):743-8. DOI: 10.1016/s0015-0282(00)01500-4. View

14.

Power L, Lefas G, Lambert P, Kim D, Evaniuk D, Lotocki R . Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival. Obstet Gynecol. 2016; 127(5):837-847. DOI: 10.1097/AOG.0000000000001396. View

15.

Wiffen P, Derry S, Bell R, Rice A, Tolle T, Phillips T . Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017; 6:CD007938. PMC: 6452908. DOI: 10.1002/14651858.CD007938.pub4. View

16.

Cobin R, Goodman N . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE. Endocr Pract. 2017; 23(7):869-880. DOI: 10.4158/EP171828.PS. View

17.

Disaia P, Grosen E, Kurosaki T, Gildea M, Cowan B, Anton-Culver H . Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol. 1996; 174(5):1494-8. DOI: 10.1016/s0002-9378(96)70594-x. View

18.

LaCroix A, Freeman E, Larson J, Carpenter J, Joffe H, Reed S . Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. Maturitas. 2012; 73(4):361-8. PMC: 3645479. DOI: 10.1016/j.maturitas.2012.09.006. View

19.

Ten Broeke S, van der Klift H, Tops C, Aretz S, Bernstein I, Buchanan D . Cancer Risks for PMS2-Associated Lynch Syndrome. J Clin Oncol. 2018; 36(29):2961-2968. PMC: 6349460. DOI: 10.1200/JCO.2018.78.4777. View

20.

Bodner K, Laubichler P, Kimberger O, Czerwenka K, Zeillinger R, Bodner-Adler B . Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Anticancer Res. 2010; 30(4):1341-5. View